Trial reportESC heart failure2018
Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study.
Trial report in ESC heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials.ESC heart failure · 2025Pooled it
- Non-invasive Autonomic Neuromodulation Is Opening New Landscapes for Cardiovascular Diseases.Frontiers in physiology · 2020Pooled it
- Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study.ESC heart failure · 2018Trial
- Hypertension: a missing piece in HFpEF?Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Single-Electrode, Bidirectional Control of Heart Rate via Vagus Nerve Modulation in Rat Model.IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society · 2026Article
- Long-term dietary allyl isothiocyanate, a TRPA1 agonist, ameliorates cardiac fibrosis and diastolic dysfunction in aged mice.GeroScience · 2025Article
- Towards spatially selective efferent neuromodulation: anatomical and functional organization of cardiac fibres in the porcine cervical vagus nerve.The Journal of physiology · 2025Article
- Autonomic neuromodulation for cardiomyopathy associated with metabolic syndrome - Prevention of precursors for heart failure with preserved ejection fraction.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Review
- Vagus nerve electrical stimulation in the recovery of upper limb motor functional impairment after ischemic stroke.Cognitive neurodynamics · 2024Review
- Importance of timing optimization for closed-loop applications of vagus nerve stimulation.Bioelectronic medicine · 2023Review
- Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimer's disease.Frontiers in physiology · 2023Review
- Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction.Cardiac failure review · 2023Review
- Closed-Loop Vagus Nerve Stimulation for the Treatment of Cardiovascular Diseases: State of the Art and Future Directions.Frontiers in cardiovascular medicine · 2022Review
- Vagus nerve stimulation activates nucleus of solitary tract neurons via supramedullary pathways.The Journal of physiology · 2021Article
- Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2021Review
- The evolving obesity challenge: targeting the vagus nerve and the inflammatory reflex in the response.Pharmacology & therapeutics · 2021Review
- Non-invasive vagus nerve stimulation attenuates proinflammatory cytokines and augments antioxidant levels in the brainstem and forebrain regions of Dahl salt sensitive rats.Scientific reports · 2020Article
- Early rehabilitation after stroke: relationship between the heart rate variability and functional outcome.ESC heart failure · 2020Article
- Autonomic Modulation for Cardiovascular Disease.Frontiers in physiology · 2020Review
- Optogenetic Control of the Peripheral Nervous System.Cold Spring Harbor perspectives in medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproximately half of the patients presenting with new-onset heart failure (HF) have HF with preserved left ventricular ejection fraction (HFpEF) and HF with mid-range left ventricular ejection fraction (HFmrEF). These patients have neurohormonal activation like that of HF with reduced ejection fraction; however, beta-blockers and angiotensin-converting enzyme inhibitors have not been shown to improve their outcomes, and current treatment for these patients is symptom based and empiric. Sympathoinhibition using parasympathetic stimulation has been shown to improve central and peripheral aspects of the cardiac nervous system, reflex control, induce myocyte cardioprotection, and can lead to regression of left ventricular hypertrophy. Beneficial effects of autonomic regulation therapy (ART) using vagus nerve stimulation (VNS) have also been observed in several animal models of HFpEF, suggesting a potential role for ART in patients with this disease.
methodsThe Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Patients with Heart Failure and Preserved Ejection Fraction (ANTHEM-HFpEF) study is designed to evaluate the feasibility, tolerability, and safety of ART using right cervical VNS in patients with chronic, stable HFpEF and HFmrEF. Patients with symptomatic HF and HFpEF or HFmrEF fulfilling the enrolment criteria will receive chronic ART with a subcutaneous VNS system attached to the right cervical vagus nerve. Safety parameters will be continuously monitored, and cardiac function and HF symptoms will be assessed every 3 months during a post-titration follow-up period of at least 12 months.
conclusionsThe ANTHEM-HFpEF study is likely to provide valuable information intended to expand our understanding of the potential role of ART in patients with chronic symptomatic HFpEF and HFmrEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.